Zhang Wei-Zheng, Chin Kok-Yong, Zakaria Roshaya, Hassan Nor Haty
Department of Nursing, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Healthcare (Basel). 2025 Apr 25;13(9):994. doi: 10.3390/healthcare13090994.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with transarterial chemoembolisation (TACE) being a primary treatment for intermediate-stage disease. However, post-procedural pain remains a significant challenge due to inconsistent management practices and a lack of standardised protocols. This scoping review synthesises current evidence on pain management strategies in HCC patients undergoing TACE, evaluates their effectiveness, identifies practice gaps, and proposes optimisation strategies. : A comprehensive database search according to the methodological approach given by Arksey and O'Malley with the aid of the PRISMA-ScR guidelines across Cochrane Library, Web of Science, CINAHL, PubMed, and Scopus was performed. The terms associated with pain, TACE, and liver cancer were included in the search strategy. Two independent researchers systematically screened study titles, abstracts, and full texts and extracted key study characteristics and approaches to pain management. : Of 1515 identified studies, 29 met the inclusion criteria. Most (72.7%) focused on pharmacological interventions, with dexamethasone and lidocaine being the most frequently investigated agents. Non-pharmacological approaches, including psychological interventions, physical therapies, music therapy, health education, and comprehensive nursing, were also reported. Pain was primarily assessed using the visual analogue scale (VAS) and numeric rating scale (NRS). : Pharmacological interventions, particularly dexamethasone and lidocaine, remain the cornerstone of pain management in TACE, yet consensus on their optimal use is lacking. Non-pharmacological strategies provide complementary benefits. standardised, evidence-based pain management protocols integrating both approaches are needed. Future large-scale, multicentre trials are essential to establish the most effective strategies for optimising patient outcomes.
肝细胞癌(HCC)是癌症相关死亡的主要原因之一,经动脉化疗栓塞术(TACE)是中期疾病的主要治疗方法。然而,由于管理方法不一致且缺乏标准化方案,术后疼痛仍然是一个重大挑战。本范围综述综合了目前关于接受TACE治疗的HCC患者疼痛管理策略的证据,评估了其有效性,确定了实践差距,并提出了优化策略。:根据Arksey和O'Malley给出的方法,借助PRISMA-ScR指南,在Cochrane图书馆、科学网、CINAHL、PubMed和Scopus上进行了全面的数据库搜索。搜索策略中纳入了与疼痛、TACE和肝癌相关的术语。两名独立研究人员系统地筛选了研究标题、摘要和全文,并提取了关键研究特征和疼痛管理方法。:在1515项已识别的研究中,29项符合纳入标准。大多数研究(72.7%)侧重于药物干预,地塞米松和利多卡因是研究最频繁的药物。还报告了非药物方法,包括心理干预、物理治疗、音乐治疗、健康教育和综合护理。疼痛主要使用视觉模拟量表(VAS)和数字评分量表(NRS)进行评估。:药物干预,特别是地塞米松和利多卡因,仍然是TACE疼痛管理的基石,但在其最佳使用方面缺乏共识。非药物策略提供了互补的益处。需要整合这两种方法标准化的、基于证据的疼痛管理方案。未来大规模、多中心试验对于确定优化患者预后的最有效策略至关重要。